Tasso, a provider of clinical-grade blood collection solutions, has forged a partnership with United BioSource (UBC), to advance decentralised sample collection and analysis solutions for post-approval research.

United BioSource is engaged in providing evidence development solutions for the biopharmaceutical industry.

Through their collaboration, the two US-based companies aim to enhance sample collection and analysis methods for post-approval research. The intention of the partners is to streamline processes, make them more efficient, and increase convenience, with the aim of improving both study designs and the patient experience.

The partnership will combine Tasso’s at-home, virtually painless, clinical-grade blood sample collection devices and comprehensive collection and analysis solutions with United BioSource’s proficiency in late-stage research.

United BioSource will bring its expertise in evidence development, participant support services, digital recruitment and engagement strategies, real-world data infrastructure, and swift analytics software to the partnership.

Biopharmaceutical companies wanting to enhance participant retention and compliance are expected to benefit from the jointly offered solution from Tasso and United BioSource. The solution will also help them boost engagement of patients, and recruit more diverse patient populations in decentralised post-approval studies.

United BioSource evidence development head Aaron Berger said: “With today’s rapidly evolving post-approval drug development requirements, there’s a real need to help sponsors efficiently, effectively, and safely execute and manage late-stage and real-world evidence generation research programmes that meet regulatory and payer requirements and support their product commercialisation objectives.

“Our partnership with Tasso allows us to collectively provide flexible, integrated and innovative offerings that improve the patient experience and advance decentralised research methods.”

Recently, Tasso and United BioSource have won a late-stage biomarker monitoring study. Additional projects are anticipated to be awarded to the partners.

Tasso CEO and co-founder Ben Casavant said: “This collaboration combines UBC’s expertise in modernised study design and execution with our innovative offerings to create an unprecedented new solution for patient-centric, decentralised research.

“Importantly, the collaboration will not only provide sponsors with the high-quality data they require but will also drive much-needed improvement in the patient experience and trial participant diversity.”

Earlier this month, Tasso partnered with Aptar Digital Health to facilitate blood sample collection for various indications including chronic conditions and oncology.